在肌缩侧面硬化症患者的息护理
Sebastiano Mercadante1, Lou'i Al-Husinat2
1Main Regional Center of Pain Relief and Supportive/Palliative Care (S.M.), La Maddalena Cancer Center, Palermo, Italy; Regional Home Care Program, SAMOT (S.M.), Palermo, Italy.
Journal of pain and symptom management
|June 28, 2023
概括
息治疗对于肌缩性侧面硬化症 (ALS) 患者至关重要,改善生活质量和症状. 缓和护理和预先护理计划的早期整合确保了在整个疾病进展过程中以患者为中心的支持.
科学领域:
- 神经学 神经学
- 抚慰性医学是一种缓解性医学.
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种渐进的,无法治愈的神经退行性运动神经元疾病.
- 由于疾病的进化性质,息护理原则是必不可少的.
研究的目的:
- 强调息治疗在治疗ALS中的重要性.
- 突出早期和多学科干预的好处.
主要方法:
- 在ALS的背景下审查息护理原则.
- 讨论多学科团队的参与.
- 探索预先护理规划策略的探索.
主要成果:
- 息治疗的参与改善了ALS患者的生活质量,症状管理和预后.
- 缓和护理的早期启动有助于以患者为中心的护理和有效的沟通.
- 提前护理规划使医疗治疗与患者的价值观和目标保持一致.
结论:
- 多学科息治疗对于全面的ALS管理至关重要.
- 解决关键的支持性护理问题 (认知,心理,疼痛,营养,通风) 是至关重要的.
- 有效的沟通和对息镇静的考虑在ALS生命终端护理中至关重要.
相关概念视频
Continuing Care
1.5K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.5K
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Cross-bridge Cycle
117.7K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.7K
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
Parkinson's Disease: Overview
607
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
607


